Regenerative Medicine Vol. 15 No. 4 | Special Report

Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement


In the South Korean health technology assessment system, prices of alternative medicines, incremental cost–effectiveness ratios in pharmaco-economic evaluations and patient access improvement systems such as risk-sharing agreements are the most important factors concerning the reimbursement of regenerative medicine (RM). Research and development companies in RM should review the key features of these medicines throughout the product development cycle to increase the probability of successful reimbursement. In addition, the South Korean government should take steps to improve the system to reflect the unique characteristics and value of RM in the reimbursement and pricing policy, to revitalize research and development, and increase patient access.

View the full article